Alimentary Pharmacology & Therapeutics
Our cohort of patients in the IMBrave150 group had a median OS of 26.5 months and a median PFS of 7.4 months, which were longer than in the phase 3 trial. ・Patients who did not meet the criteria for the phase 3 trial, particularly those with mALBI grade 1 or 2a, had an equally good prognosis. Summary Background Atezolizumab plus bevacizumab...
Alimentary Pharmacology &Therapeutics, EarlyView.
Alimentary Pharmacology &Therapeutics, EarlyView.
Alimentary Pharmacology &Therapeutics, EarlyView.
Alimentary Pharmacology &Therapeutics, Volume 59, Issue 11, Page 1465-1466, June 2024.
Alimentary Pharmacology &Therapeutics, Volume 59, Issue 11, Page 1446-1447, June 2024.
خوراک خبری خود را بسازید
آیا آماده هستید تا آن را اجرا کنید؟
بدون نیاز به کارت اعتباری، یک دوره آزمایشی 14 روزه را شروع کنید.